ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to advance Anktiva in non-small cell lung cancer.

We recently compiled a list of the 10 Firms Lead Thursday’s Rally on Better Earnings, Bargain-Hunting. In this article, we ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

In this article, we will take a look at the 12 stocks that will double in 2025.

The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

Mutual Advisors LLC bought a new position in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).

ImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

Snappt, the trusted leader in fraud detection for multifamily property management, today released its 2024 Fraud Report: Data, Trends, and Strategies for 2025. The report provides insights from its ...

Sidney, a book developer and publisher, announced today the publication of YOU ARE THE DOCTOR: The Importance of a Team Approach in Cancer Treatment by the late Susan Finlay Dunbar, MD. A unique ...